Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Inclusion Criteria

• •For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
• •Confirmed diagnosis of previously treated multiple myeloma with progression documented by criteria of the International Myeloma Working Group after or during the most recent therapy
• •Patient received 5 or fewer prior lines of therapy
• •Eastern Cooperative Oncology Group performance status of 0 or 1 (safety lead-in cohort) or 0 to 2 (additional patients)
• •Measurable disease as defined by at least 1 of the following:
• •* Serum immunoglobulin (Ig)G, IgA, IgM, or monoclonal (M) protein level ≥0.5 g/dL or serum IgD M protein level ≥0.05 g/dL; or
• •* Urine M protein level ≥200 mg excreted in a 24-hour collection sample; or
• •* Involved serum free light chain level ≥10 mg/dL, provided the free light chain ratio is abnormal